Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Lancet Oncol

Retrieve available abstracts of 95 articles:
HTML format
Text format



Single Articles


    November 2017
  1. WEISS J
    Bevacizumab in adjuvant treatment of non-small-cell lung cancer.
    Lancet Oncol. 2017 Nov 9. pii: S1470-2045(17)30843.
    PubMed     Text format    


  2. WAKELEE HA, Dahlberg SE, Keller SM, Tester WJ, et al
    Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
    Lancet Oncol. 2017 Nov 9. pii: S1470-2045(17)30691.
    PubMed     Text format     Abstract available


    October 2017
  3. SHAW AT, Felip E, Bauer TM, Besse B, et al
    Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Lancet Oncol. 2017 Oct 23. pii: S1470-2045(17)30680.
    PubMed     Text format     Abstract available


  4. DE KONING HJ
    Lung cancer screening and its continuous risk assessment.
    Lancet Oncol. 2017 Oct 16. pii: S1470-2045(17)30730.
    PubMed     Text format    


  5. TAMMEMAGI MC, Schmidt H, Martel S, McWilliams A, et al
    Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
    Lancet Oncol. 2017 Oct 16. pii: S1470-2045(17)30597.
    PubMed     Text format     Abstract available


  6. FAIVRE-FINN C, Ryder WD, Blackhall F
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer? - Authors' reply.
    Lancet Oncol. 2017;18:e556.
    PubMed     Text format    


  7. EZE C, Roengvoraphoj O, Dantes M, Manapov F, et al
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
    Lancet Oncol. 2017;18:e555.
    PubMed     Text format    


  8. MITIN T, Farrell M, Holland J, Cetnar J, et al
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
    Lancet Oncol. 2017;18:e554.
    PubMed     Text format    


  9. ZENG H, Yu J, Yuan S
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
    Lancet Oncol. 2017;18:e553.
    PubMed     Text format    


  10. VAN ZANDWIJK N, Pavlakis N, Kao SC, Linton A, et al
    Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
    Lancet Oncol. 2017;18:1386-1396.
    PubMed     Text format     Abstract available


  11. PAVEL ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, et al
    Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase
    Lancet Oncol. 2017;18:1411-1422.
    PubMed     Text format     Abstract available


    September 2017
  12. BRUECKL WM
    Treatment choice in EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2017 Sep 25. pii: S1470-2045(17)30684.
    PubMed     Text format    


  13. WU YL, Cheng Y, Zhou X, Lee KH, et al
    Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
    Lancet Oncol. 2017 Sep 25. pii: S1470-2045(17)30608.
    PubMed     Text format     Abstract available


  14. PLANCHARD D, Smit EF, Groen HJM, Mazieres J, et al
    Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
    Lancet Oncol. 2017 Sep 8. pii: S1470-2045(17)30679.
    PubMed     Text format     Abstract available


  15. PERROT M, Wu L, Wu M, Cho BCJ, et al
    Radiotherapy for the treatment of malignant pleural mesothelioma.
    Lancet Oncol. 2017;18:e532-e542.
    PubMed     Text format     Abstract available


  16. MAIO M, Scherpereel A, Calabro L, Aerts J, et al
    Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
    Lancet Oncol. 2017;18:1261-1273.
    PubMed     Text format     Abstract available


    July 2017
  17. AKAMATSU H, Takahashi T, Yamamoto N
    Prophylactic cranial irradiation in small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2017;18:e369.
    PubMed     Text format    


  18. FAN X, Liang F, Zhu J
    Prophylactic cranial irradiation in small-cell lung cancer.
    Lancet Oncol. 2017;18:e368.
    PubMed     Text format    


  19. WEISS GJ, Lohinai Z
    Prophylactic cranial irradiation in small-cell lung cancer.
    Lancet Oncol. 2017;18:e367.
    PubMed     Text format    


  20. MANAPOV F, Eze C
    Prophylactic cranial irradiation in small-cell lung cancer.
    Lancet Oncol. 2017;18:e366.
    PubMed     Text format    


  21. RUSTHOVEN CG, Kavanagh BD
    Prophylactic cranial irradiation in small-cell lung cancer.
    Lancet Oncol. 2017;18:e365.
    PubMed     Text format    


  22. DEL PAGGIO JC, Sullivan R, Schrag D, Hopman WM, et al
    Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
    Lancet Oncol. 2017;18:887-894.
    PubMed     Text format     Abstract available


    June 2017
  23. BROWER V
    Atezolizumab in advanced non-small-cell lung cancer.
    Lancet Oncol. 2017 Jun 22. pii: S1470-2045(17)30504.
    PubMed     Text format    


  24. FAIVRE-FINN C, Snee M, Ashcroft L, Appel W, et al
    Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
    Lancet Oncol. 2017 Jun 19. pii: S1470-2045(17)30318.
    PubMed     Text format     Abstract available


  25. FIETKAU R
    Which fractionation of radiotherapy is best for limited-stage small-cell lung cancer?
    Lancet Oncol. 2017 Jun 19. pii: S1470-2045(17)30439.
    PubMed     Text format    


  26. SHAW AT, Kim TM, Crino L, Gridelli C, et al
    Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Lancet Oncol. 2017 Jun 8. pii: S1470-2045(17)30339.
    PubMed     Text format     Abstract available


    May 2017
  27. SHAVERDIAN N, Lisberg AE, Bornazyan K, Veruttipong D, et al
    Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
    Lancet Oncol. 2017 May 24. pii: S1470-2045(17)30380.
    PubMed     Text format     Abstract available


  28. DAS M
    Brigatinib effective in ALK-positive non-small-cell lung cancer.
    Lancet Oncol. 2017 May 11. pii: S1470-2045(17)30342.
    PubMed     Text format    


    March 2017
  29. GULLEY JL, Rajan A, Spigel DR, Iannotti N, et al
    Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
    Lancet Oncol. 2017 Mar 31. pii: S1470-2045(17)30240.
    PubMed     Text format     Abstract available


  30. TAKAHASHI T, Yamanaka T, Seto T, Harada H, et al
    Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial.
    Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30230.
    PubMed     Text format     Abstract available


  31. SLOTMAN BJ
    Time to reconsider prophylactic cranial irradiation in extensive-stage small-cell lung cancer?
    Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30193.
    PubMed     Text format    


  32. BROWER V
    Pravastatin has no advantage in small-cell lung cancer.
    Lancet Oncol. 2017 Mar 9. pii: S1470-2045(17)30184.
    PubMed     Text format    


    February 2017
  33. SCOTT JG, Berglund A, Schell MJ, Mihaylov I, et al
    A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.
    Lancet Oncol. 2017;18:202-211.
    PubMed     Text format     Abstract available


    January 2017
  34. BURKI TK
    Treatment options not taken for non-small-cell lung cancer.
    Lancet Oncol. 2017 Jan 27. pii: S1470-2045(17)30066.
    PubMed     Text format    


  35. MAYOR S
    Osimertinib effective in EGFR T790M-positive lung cancer.
    Lancet Oncol. 2017;18:e9.
    PubMed     Text format    


    December 2016
  36. BROWER V
    Onartuzumab ineffective in non-small-cell lung cancer.
    Lancet Oncol. 2016 Dec 22. pii: S1470-2045(16)30680.
    PubMed     Text format    


  37. RUDIN CM, Pietanza MC, Bauer TM, Ready N, et al
    Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
    Lancet Oncol. 2016 Dec 2. pii: S1470-2045(16)30565.
    PubMed     Text format     Abstract available


  38. HELLMANN MD, Rizvi NA, Goldman JW, Gettinger SN, et al
    Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
    Lancet Oncol. 2016 Dec 2. pii: S1470-2045(16)30624.
    PubMed     Text format     Abstract available


  39. LIN JJ, Shaw AT
    Raising the bar on first-line immunotherapy in lung cancer.
    Lancet Oncol. 2016 Dec 2. pii: S1470-2045(16)30594.
    PubMed     Text format    


  40. ROSSI A
    Rovalpituzumab tesirine and DLL3: a new challenge for small-cell lung cancer.
    Lancet Oncol. 2016 Dec 2. pii: S1470-2045(16)30575.
    PubMed     Text format    


    November 2016
  41. GADGEEL SM
    Drug selection for anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Lancet Oncol. 2016 Nov 7. pii: S1470-2045(16)30567.
    PubMed     Text format    


  42. GETTINGER SN, Bazhenova LA, Langer CJ, Salgia R, et al
    Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Lancet Oncol. 2016 Nov 7. pii: S1470-2045(16)30392.
    PubMed     Text format     Abstract available


  43. NEAL JW, Dahlberg SE, Wakelee HA, Aisner SC, et al
    Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
    Lancet Oncol. 2016 Nov 4. pii: S1470-2045(16)30561.
    PubMed     Text format     Abstract available


  44. ROSELL R, Karachaliou N
    RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancer.
    Lancet Oncol. 2016 Nov 4. pii: S1470-2045(16)30557.
    PubMed     Text format    


  45. DRILON A, Rekhtman N, Arcila M, Wang L, et al
    Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
    Lancet Oncol. 2016 Nov 4. pii: S1470-2045(16)30562.
    PubMed     Text format     Abstract available


    October 2016
  46. GOMEZ DR, Blumenschein GR Jr, Lee JJ, Hernandez M, et al
    Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.
    Lancet Oncol. 2016 Oct 24. pii: S1470-2045(16)30532.
    PubMed     Text format     Abstract available


  47. GOSS G, Tsai CM, Shepherd FA, Bazhenova L, et al
    Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
    Lancet Oncol. 2016 Oct 14. pii: S1470-2045(16)30508.
    PubMed     Text format     Abstract available


  48. LANGER CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, et al
    Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
    Lancet Oncol. 2016 Oct 10. pii: S1470-2045(16)30498.
    PubMed     Text format     Abstract available


  49. LE PECHOUX C
    PCI in resected small-cell lung cancer - Author's reply.
    Lancet Oncol. 2016;17:e416.
    PubMed     Text format    


  50. KNISELY J, Sharma R, Goenka A, Halthore A, et al
    PCI in resected small-cell lung cancer.
    Lancet Oncol. 2016;17:e415.
    PubMed     Text format    


    September 2016
  51. UMEWENI N, Knight H, McVeigh G
    NICE guidance on necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer.
    Lancet Oncol. 2016 Sep 27. pii: S1470-2045(16)30488.
    PubMed     Text format    


  52. WALLINGTON M, Saxon EB, Bomb M, Smittenaar R, et al
    30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study.
    Lancet Oncol. 2016;17:1203-16.
    PubMed     Text format     Abstract available


    August 2016
  53. BURKI TK
    Predicting lung cancer prognosis using machine learning.
    Lancet Oncol. 2016 Aug 25. pii: S1470-2045(16)30436.
    PubMed     Text format    


  54. HALL CJ, Umeweni N, Knight H, Smith L, et al
    NICE guidance on ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer.
    Lancet Oncol. 2016 Aug 23. pii: S1470-2045(16)30435.
    PubMed     Text format    


  55. TAN WL, Jain A, Takano A, Newell EW, et al
    Novel therapeutic targets on the horizon for lung cancer.
    Lancet Oncol. 2016;17:e347-62.
    PubMed     Text format     Abstract available


  56. LICHT PB, Andersen C, Dan Jorgensen O, Bendixen M, et al
    Quality of life after video-assisted surgery for lung cancer - Author's reply.
    Lancet Oncol. 2016;17:e318-9.
    PubMed     Text format    


  57. NAKAZAWA S, Shimizu K, Nagashima T, Mogi A, et al
    Quality of life after video-assisted surgery for lung cancer.
    Lancet Oncol. 2016;17:e318.
    PubMed     Text format    


  58. THE VIOLET TRIALISTS CORRESPON
    Quality of life after video-assisted surgery for lung cancer.
    Lancet Oncol. 2016;17:e317.
    PubMed     Text format    


  59. VERONESI G, Novellis P, Park B
    Quality of life after video-assisted surgery for lung cancer.
    Lancet Oncol. 2016;17:e316-7.
    PubMed     Text format    


  60. MEHRAN RJ, Roth JA
    Quality of life after video-assisted surgery for lung cancer.
    Lancet Oncol. 2016;17:e315-6.
    PubMed     Text format    


    July 2016
  61. PECHOUX CL, Sun A, Slotman BJ, De Ruysscher D, et al
    Prophylactic cranial irradiation for patients with lung cancer.
    Lancet Oncol. 2016;17:e277-93.
    PubMed     Text format     Abstract available


    June 2016
  62. GOTO K, Ohe Y, Shibata T, Seto T, et al
    Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Lancet Oncol. 2016 Jun 13. pii: S1470-2045(16)30104.
    PubMed     Text format     Abstract available


  63. KALEMKERIAN GP
    Combination chemotherapy for relapsed small-cell lung cancer.
    Lancet Oncol. 2016 Jun 13. pii: S1470-2045(16)30160.
    PubMed     Text format    


  64. BALDWIN DR, Devaraj A
    Lung cancer risk in new pulmonary nodules: implications for CT screening and nodule management.
    Lancet Oncol. 2016 Jun 6. pii: S1470-2045(16)30134.
    PubMed     Text format    


  65. WALTER JE, Heuvelmans MA, de Jong PA, Vliegenthart R, et al
    Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial.
    Lancet Oncol. 2016 Jun 6. pii: S1470-2045(16)30069.
    PubMed     Text format     Abstract available


  66. ANTONIA SJ, Lopez-Martin JA, Bendell J, Ott PA, et al
    Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
    Lancet Oncol. 2016 Jun 3. pii: S1470-2045(16)30098.
    PubMed     Text format     Abstract available


  67. LI Y, Wu YL
    Immunotherapy for small-cell lung cancer.
    Lancet Oncol. 2016 Jun 3. pii: S1470-2045(16)30159.
    PubMed     Text format    


  68. GOLDBERG SB, Gettinger SN, Mahajan A, Chiang AC, et al
    Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
    Lancet Oncol. 2016 Jun 3. pii: S1470-2045(16)30053.
    PubMed     Text format     Abstract available


  69. PLANCHARD D, Besse B, Groen HJ, Souquet PJ, et al
    Dabrafenib plus trametinib in patients with previously treated BRAF-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
    Lancet Oncol. 2016 Jun 3. pii: S1470-2045(16)30146.
    PubMed     Text format     Abstract available


    May 2016
  70. BENDIXEN M, Jorgensen OD, Kronborg C, Andersen C, et al
    Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial.
    Lancet Oncol. 2016 May 6. pii: S1470-2045(16)00173.
    PubMed     Text format     Abstract available


    April 2016
  71. VANSTEENKISTE JF, Cho BC, Vanakesa T, De Pas T, et al
    Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2016 Apr 27. pii: S1470-2045(16)00099.
    PubMed     Text format     Abstract available


  72. QUOIX E
    Post-operative survival of patients with lung cancer.
    Lancet Oncol. 2016 Apr 27. pii: S1470-2045(16)30031.
    PubMed     Text format    


  73. PARK K, Tan EH, O'Byrne K, Zhang L, et al
    Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
    Lancet Oncol. 2016 Apr 12. pii: S1470-2045(16)30033.
    PubMed     Text format     Abstract available


  74. PLANCHARD D, Kim TM, Mazieres J, Quoix E, et al
    Dabrafenib in patients with BRAF-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
    Lancet Oncol. 2016 Apr 11. pii: S1470-2045(16)00077.
    PubMed     Text format     Abstract available


    March 2016
  75. FIELD JK, Duffy SW
    Lung cancer CT screening: is annual screening necessary?
    Lancet Oncol. 2016 Mar 18. pii: S1470-2045(16)00079.
    PubMed     Text format    


  76. PATZ EF JR, Greco E, Gatsonis C, Pinsky P, et al
    Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial.
    Lancet Oncol. 2016 Mar 18. pii: S1470-2045(15)00621.
    PubMed     Text format     Abstract available


  77. KIM DW, Mehra R, Tan DS, Felip E, et al
    Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
    Lancet Oncol. 2016 Mar 10. pii: S1470-2045(15)00614.
    PubMed     Text format     Abstract available


  78. BURKI TK
    Counting the cost of end-of-life cancer care.
    Lancet Oncol. 2016;17:e91.
    PubMed     Text format    


  79. GARON EB
    The race for combined checkpoint inhibition in NSCLC.
    Lancet Oncol. 2016;17:259-60.
    PubMed     Text format    


    February 2016
  80. TEMEL JS, Abernethy AP, Currow DC, Friend J, et al
    Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.
    Lancet Oncol. 2016 Feb 19. pii: S1470-2045(15)00558.
    PubMed     Text format     Abstract available


  81. ANTONIA S, Goldberg SB, Balmanoukian A, Chaft JE, et al
    Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
    Lancet Oncol. 2016 Feb 5. pii: S1470-2045(15)00544.
    PubMed     Text format     Abstract available


  82. CHANG JY, Senan S, Smit EF, Roth JA, et al
    Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2016;17:e42-3.
    PubMed     Text format    


  83. KATZ MS, Husain ZA
    Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer.
    Lancet Oncol. 2016;17:e41-2.
    PubMed     Text format    


  84. RIESTERER O, Weder W, Stahel R
    Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power? - Authors' reply.
    Lancet Oncol. 2016;17:e44-5.
    PubMed     Text format    


  85. RIMNER A, Simone CB 2nd, Zauderer MG, Cengel KA, et al
    Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?
    Lancet Oncol. 2016;17:e43-4.
    PubMed     Text format    


  86. HARDING E
    The Lake.
    Lancet Oncol. 2016;17:151.
    PubMed     Text format    


  87. BAKER H
    Familial risk in patients with carcinoma of unknown primary.
    Lancet Oncol. 2016;17:e48.
    PubMed     Text format    


  88. JASSEM J
    Alectinib in crizotinib-resistant, ALK-positive NSCLC.
    Lancet Oncol. 2016;17:134-5.
    PubMed     Text format    


    December 2015
  89. QUOIX E, Lena H, Losonczy G, Forget F, et al
    TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
    Lancet Oncol. 2015 Dec 22. pii: S1470-2045(15)00483.
    PubMed     Text format     Abstract available


  90. BUTTS CA, Sangha R
    TIME for a successful cancer vaccine in NSCLC?
    Lancet Oncol. 2015 Dec 22. pii: S1470-2045(15)00554.
    PubMed     Text format    


  91. SHAW AT, Gandhi L, Gadgeel S, Riely GJ, et al
    Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
    Lancet Oncol. 2015 Dec 18. pii: S1470-2045(15)00488.
    PubMed     Text format     Abstract available


  92. BROWER V
    Afatinib and chemotherapy in non-small-cell lung cancer.
    Lancet Oncol. 2015 Dec 17. pii: S1470-2045(15)00609.
    PubMed     Text format    


    October 2015
  93. FUSI A, Festino L, Botti G, Masucci G, et al
    PD-L1 expression as a potential predictive biomarker.
    Lancet Oncol. 2015;16:1285-7.
    PubMed     Text format    


    September 2015
  94. VASSAL G, Blanc P, Copland C, Pearson A, et al
    Will the revised class waiver list make it?
    Lancet Oncol. 2015;16:e425-6.
    PubMed     Text format    


  95. RICE D, Sepesi B, Heymach J, Swisher S, et al
    SABR vs surgery for NSCLC in the media.
    Lancet Oncol. 2015;16:e422.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: